Asset profile
Canagliflozin · Invokana
Small molecule
Evidence outlook
Approved: Chronic Kidney Disease, Type 2 Diabetes
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Reliable signal
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
128 competitors in this universe: 10 direct rivals (same mechanism and indication), 1 same-class, 117 same-indication.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Canagliflozin (Invokana): this drug | Approved | Small molecule | SGLT2 | ||
| Bexagliflozin (Brenzavvy) | Approved | Small molecule | SGLT2 | ||
| Dapagliflozin (Farxiga / Forxiga) | Approved | Small molecule | SGLT2 | ||
| Empagliflozin (Jardiance) | Approved | Small molecule | SGLT2 | ||
| Ertugliflozin (Steglatro) | Approved | Small molecule | SGLT2 | ||
| DWP16001 (Enavogliflozin) | Phase 3 | Small molecule | SGLT2 | ||
| Janagliflozin | Phase 3 | Small molecule | SGLT2 | ||
| THR-1442 | Phase 3 | Small molecule | SGLT2 | ||
| DA-2811 | Phase 2 | Small molecule | SGLT2 | ||
| Tofogliflozin (Apleway / Deberza) | Phase 2 | Small molecule | SGLT2 | ||
| Rongliflozin | Phase 1 | Small molecule | SGLT2 | ||
| Zibotentan + Dapagliflozin | Phase 3 | Small molecule | Endothelin A receptor, SGLT2 | ||
| Afrezza | Approved | Peptide | Insulin receptor (basal), Insulin | ||
| Alogliptin (Nesina) | Approved | Small molecule | DPP-4 | ||
| Atrasentan (Vanrafia) | Approved | Small molecule | Endothelin A receptor | ||
| Avacopan (Tavneos) | Approved | Small molecule | Complement C5a receptor 1 (C5aR1/CD88) |
…and 113 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
4 further head-to-head pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
(11 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (3)
October 2026 (1)
What to watch
2027 (4)
January 2027 (1)
What to watch
July 2027 (1)
What to watch
October 2027 (2)
What to watch
What to watch
2028 (3)
February 2028 (1)
What to watch
March 2028 (1)
What to watch
July 2028 (1)
What to watch
2029 (1)
March 2029 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.